The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy

In the present study, an elevated plasma CRP (⩾8.6 mg l−1) has been identified as a prognostic factor for poor CSS, OS and DFS in prostate cancer patients undergoing radiotherapy. The association between elevated CRP levels and poor prognosis was independent of other measures of prognosis such as tumour stage, Gleason grading and prostate specific antigen (PSA) level at diagnosis. If confirmed by additional studies, our findings may contribute to future individual risk assessment in prostate cancer patients.